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Introduction
Hydrocephalus is a condition that affects nearly 1 million Americans and is characterized by the excessive 
accumulation of  cerebrospinal fluid (CSF) in the brain. While people of  any age may be affected, hydro-
cephalus is most commonly diagnosed in children. Approximately 1 in 1000 newborns will require treat-
ment resulting in approximately 39,900 annual hospital admissions, with a cost of  $2 billion dollars in the 
United States alone (1). Globally, hydrocephalus disproportionally affects developing nations, and there are 
an estimated 400,000 new patients diagnosed worldwide per year (2). Untreated hydrocephalus may cause 
developmental delay, visual loss, brain damage, and death.
Hydrocephalus has multiple causes resulting in abnormalities in CSF production, circulation, or absorp-
tion. In children, hydrocephalus may be congenital or associated with spinal dysraphism, premature birth, 
tumors, infection, hemorrhage, or trauma. Adults may develop hydrocephalus from similar causes. Teenag-
ers and younger adults may develop idiopathic intracranial hypertension (IIH), previously called pseudo-
tumor cerebri. This poorly understood disease is most common in young women who are overweight and 
may cause blindness if  improperly treated. There is a growing recognition of  the role of  normal pressure 
hydrocephalus (NPH) in elderly patients. This underdiagnosed entity affects approximately 700,000 Ameri-
cans per year and is one of  the few potentially treatable causes of  dementia (3). Posttraumatic hydrocephalus 
(PTH) occurs as the result of  traumatic brain injury (TBI) (4–6). The reported prevalence of  PTH varies 
considerably, with some estimates suggesting that 0.7%–29% of  TBI patients have PTH (4, 5) while 45% of  
severe TBI patients have this condition (6).
There is no reliable pharmaceutical treatment for hydrocephalus. The only current durable treat-
ment is surgery. Certain patients with obstructive hydrocephalus are candidates for an endoscopic 
procedure that creates a bypass for CSF flow called an endoscopic third ventriculostomy (ETV). Endo-
scopic procedures are also used to coagulate the choroid plexus (CP), leading to irreversible loss of  the 
tissue. The long-term consequences of  coagulation of  the CP are unknown. The most common surgery 
is placement of  a mechanical CSF shunt. A shunt is composed of  a catheter inserted into a cerebral 
ventricle, a 1-way valve, and a distal catheter that drains fluid into another part of  the body. Approxi-
mately 4500 new shunts are placed yearly in American children (1). Shunts have a high complication 
rate both in the initial surgery and in the long-term function. Approximately 8% of  shunts will become 
infected, which leads to multiple surgeries, prolonged hospitalizations, and declines in intelligence 
Hydrocephalus is a serious condition that impacts patients of all ages. The standards of care are 
surgical options to divert, or inhibit production of, cerebrospinal fluid; to date, there are no effective 
pharmaceutical treatments, to our knowledge. The causes vary widely, but one commonality of this 
condition is aberrations in salt and fluid balance. We have used a genetic model of hydrocephalus 
to show that ventriculomegaly can be alleviated by inhibition of the transient receptor potential 
vanilloid 4, a channel that is activated by changes in osmotic balance, temperature, pressure and 
inflammatory mediators. The TRPV4 antagonists do not appear to have adverse effects on the 
overall health of the WT or hydrocephalic animals.
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quotient (IQ) in children. Overall, approximately 50% of  all shunts in children will fail and require a 
revision surgery within 2 years of  placement (7).
The majority of  the CSF is produced by the CP, a small structure within the cerebral ventricles. The CP 
is composed of  a fenestrated capillary network surrounded by an epithelial monolayer forming one of  the 
most secretory epithelial tissues in the body, producing approximately 500 mL of  CSF per day in an adult 
human. The CSF production is controlled by specific electrolyte and water channels and transporters found 
in the barrier epithelial cells (8). While many of  the CP transporters are known, their composite activations 
resulting in both electrolyte and fluid flux across the epithelial cells remains incompletely characterized. The 
identity of  the intracellular regulatory proteins and processes that control these important transport proteins 
are even less well defined. This is particularly true for signaling pathways and transporters that are activated 
by pathophysiological mechanisms such as those in play during the development of  hydrocephalus.
We are studying a potential hub protein, the transient receptor potential vanilloid 4 (TRPV4) channel, 
which is expressed in both native CP (9) and in a CP-derived cell line (10, 11). Importantly, when TRPV4 
is activated, it allows Ca2+ and Na+ to enter the cell, resulting in compensatory changes in both electrolyte 
and fluid movement across the epithelial monolayer. The channel can be activated by changes in osmotic 
balance, temperature, mechanical stress (pressure), and inflammatory mediators such as arachidonic acid 
metabolites (12–15), making it a hub protein that can integrate multiple stimuli. We have previously shown 
that, in a porcine CP epithelial cell line, stimulation of  endogenous TRPV4 results in multiphasic ion flux-
es, which can be blocked by either of  2 specific TRPV4 antagonists (10).
Our current studies use a rodent model of  communicating hydrocephalus, the Wpk rat (Tmem67–/–) 
that is orthologous to a human genetic disease called Meckel-Gruber syndrome type 3 (16, 17). The affect-
ed animals carry a single nucleotide polymorphism in Tmem67, encoding one of  a complex of  proteins 
involved in formation of  the primary cilium. The homozygous affected animals have severe hydrocephalus 
and renal cystic disease, and they typically survive for 18–21 days after birth (17). The Tmem67+/– heterozy-
gous animals have milder, slowly progressing hydrocephalus, no cystic disease, and no overt symptoms of  
pain or distress until after the first year of  life (18). In the current studies, we show that — in the homozy-
gous, hydrocephalic animals — treatment with TRPV4 antagonists alleviates the development of  ventric-
ulomegaly. The drugs do not appear to have overt effects on the overall health of  the WT or hydrocephalic 
animals. The effect does not appear to be the result of  changes in TRPV4 synthesis and likely involves the 
regulation of  transporter localization and activation.
Hydrocephalus confers lifelong morbidity and possible mortality to a significant number of  patients. 
The mortality rate in patients with shunts is approximately 1% per year. Patients often suffer cognitive and 
emotional deficits, lower IQ, sensory deficits, depression, pain, and poor social function (19). Surgery is 
effective but has an inherently high complication rate and may be prohibitively expensive in developing 
nations. A durable, effective medical treatment may potentially revolutionize care for a large number of  
patients. Our goal is to provide a preclinical basis for consideration of  TRPV4 as a potential drug target in 
the treatment of  hydrocephalus, and the efficacy of  TRPV4 antagonists in a genetic model of  the disease 
represents an initial step toward that goal.
Results
Tmem67–/– rats develop hydrocephalus that is ameliorated by treatment with 2 different TRPV4 antagonists. Much 
like children with hydrocephalus, the Tmem67–/– rat pups develop megalocephaly (cranial enlargement and 
doming) (Figure 1A), a characteristic that can be used to distinguish WT and homozygous animals. We 
have previously shown that the hydrocephalus in this model is a communicating form of  the disease (18) 
and has physiological effects in both the heterozygous and homozygous animals. The severity of  the hydro-
cephalus in the heterozygous animals is not sufficient to cause doming at this early stage and can only be 
detected by MRI. Our initial experiments used the cranial doming to characterize the effects of  2 structural-
ly distinct TRPV4 modulators on hydrocephalic development (Figure 1, B–E, and Figure 2, A–C).
In the first study (Figure 1), normal (WT and heterozygous) pups and hydrocephalic (homozygous) 
pups were treated daily for 9 days with vehicle (saline/DMSO), a TRPV4 agonist (GSK1016790A; 0.003 
mg/kg BW), or a TRPV4 antagonist (HC067047; 0.03 mg/kg BW) starting on P8. Cranial dimensions were 
measured after 9 days of  treatment. The hydrocephalic condition caused a statistically significant increase 
in head dimensions compared with the control animals, despite an overall decrease in BW in the affected 
pups. As shown in Figure 1, B and C, TRPV4 agonist treatment exacerbated the hydrocephalus in the 
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Figure 1. Treatment of hydrocephalic Tmem67–/– rats with TRPV4 agonist (GSK1016790A) and antagonist (HC067047). (A) Images of P15 WT 
(Tmem67+/+) and hydrocephalic (Tmem67–/–) rats demonstrating enlarged horizontal and vertical cranial dimensions, and reduced BW compared with 
WT littermates. (B–D) Vertical and horizontal head dimensions, and BWs of normal (Tmem67+/+, Tmem67+/–) and hydrocephalic (Tmem67–/–) rats taken 
at P17 after 9 days of daily i.p. treatment with either vehicle, GSK101 (TRPV4 agonist), or HC067 (TRPV4 antagonist). (E) Kidney weights of animals, 
expressed as a function of BW, at P17 after 9 days of daily treatment with either vehicle, GSK101, or HC067, demonstrating no effect of the drugs on 
overt renal phenotype. Normal, vehicle (n = 4); normal, GSK101 (n = 3); normal, HC067 (n = 4). Hydro,vehicle (n = 17); hydro, GSK101 (n = 8); hydro, HC067 
(n = 14). All data shown are the mean ± SEM for each group. Significance values were determined by 2-way ANOVA test in Prism using genotype and 
treatment as variables. Vehicle, DMSO/saline injection; GSK101, GSK1016790A, TRPV4 agonist, 0.003 mg/kg BW i.p. daily injection; HC067, HC067047, 
TRPV4 antagonist, 0.03 mg/kg BW i.p. daily injection.
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affected animals, although this effect was only statistically significant when comparing the agonist-treated 
versus vehicle-treated homozygous pups in the horizontal head dimension. Conversely, treatment with the 
TRPV4 antagonist HC067047 ameliorated the hydrocephalus as measured by either cranial dimensions.
As a surrogate of  overall health and feeding behavior, BWs were also taken at P17. Because of  the 
disease, the BWs of  the Tmem67–/– pups are consistently lower than their normal littermates. Impor-
tantly, the BWs were not further decreased by the TRPV4 antagonist treatment (Figure 1D) in the 
homozygous animals and treatment did not alter the BW in the normal animals. As reported previous-
ly, the Tmem67–/– pups have severe polycystic kidney disease (18). This is indicated by kidney weights 
as a percentage of  BW (Figure 1E). The kidney weights were not significantly altered by either agonist 
or antagonist treatment.
As proof  of  principle, we conducted a similar experiment using a structurally distinct TRPV4 antag-
onist, RN 1734 (Figure 2). In this series, the pups were treated from P7–P14. As with the HC067047, the 
second antagonist significantly inhibited the cranial expansion in both dimensions. The RN 1734 antago-
nist was chosen for more detailed studies.
While these initial data are striking, the use of  calipers to measure head dimensions is investiga-
tor dependent (experiments shown in Figure 1 and Figure 2 were conducted by a single technician 
who was blinded to the genotype and treatment of  the animals) and is not sensitive to changes in the 
heterozygous animals, which were included as part of  the normal cohort in the experiments shown 
in Figure 1 and Figure 2. We, therefore, sought to develop a more quantitative method by measuring 
lateral ventricular volume using MRI.
Quantitative measurements of  the effect of  a TRPV4 antagonist on hydrocephalic development. Figure 3 illus-
trates examples of  lateral ventricle CSF quantification using translational 3T MRI that uses the native con-
trast of  the CSF by employing a T2W 3DSPACE imaging sequence (20) in WT, heterozygous (Tmem67+/–) 
and homozygous (Tmem67–/–) rat pups over an 8-day period from P7 to P15. Vehicle-treated animals are 
compared with those treated with the TRPV4 antagonist RN 1734 (P7–P14; i.p. daily, 4 mg/kg BW). MRIs 
were conducted on P7 and P15. The lateral ventricle volumes are indicated by red and green within hori-
zontal, coronal, and sagittal views of  the brain and as stand-alone 3D renderings (Figure 3).
Figure 4 provides the summarized ventricular volume data from the MRI study, comparing the lateral ventri-
cle volumes of the vehicle-treated WT (Figure 4A), heterozygous (Figure 4B), and homozygous (Figure 4C) ani-
mals. Treatment with RN 1734 had no statistically significant effect on ventricular dilation in the WT or hetero-
zygous animals. There was an approximately 20-fold increase in ventricular volumes in the homozygous animals 
Figure 2. Amelioration of cranial doming by P15 in hydrocephalic Tmem67–/– rats by treatment with TRPV4 antagonist (RN 1734). (A and B) Vertical 
and horizontal dimensions of normal (Tmem67+/+, Tmem67+/–) and hydrocephalic (Tmem67–/–) rats taken at P15 after 7 days daily i.p. treatment with either 
vehicle or RN 1734 (TRPV4 antagonist). (C) BWs of normal and hydrocephalic rats taken at P15 after 7 days daily i.p. treatment with either vehicle or RN 
1734. Normal, vehicle (n = 26); normal, RN 1734 (n = 13). Hydro, vehicle (n = 5); hydro, RN 1734 (n = 4). All data shown are the mean ± SEM for each group. 
Significance values were determined by 2-way ANOVA test in Prism using genotype and treatment as variables. Vehicle, DMSO/saline injection; RN 1734, 
RN 1734, TRPV4 antagonist, 4 mg/kg BW i.p. daily injection.
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compared with WT at both P7 (3.73 ± 1.50 versus 62.13 ± 12.58) and P15 (7.72 ± 2.19 versus 144.28 ± 38.06). 
By contrast, treatment with the antagonist completely inhibited the ventricular dilation of the homozygous ani-
mals between P7 and P15 (Figure 4C). Thus, the increased ventricular volume in the homozygous animals is 
mitigated by RN 1734 treatment. The composite results are illustrated in the bar graph showing the differences 
(Δ) in ventricular volumes between P7 and P15 for both genotypes and treatments (Figure 4D). The differences 
that were noted during disease development and treatment were independent of sex (Supplemental Figure 1; 
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.137646DS1).
Treatment with the TRPV4 antagonist has no adverse effects on body, kidney, or brain weight in WT or hydrocephalic 
animals. As a surrogate marker of whether the animals were feeding normally, we examined the effect of  
drug treatment on BW at the end of the study. While the hydrocephalic animals had a lower BW, the TRPV4 
antagonist treatment had no effect on the BW of any of the genotypes (Figure 5A). As previously reported, 
the homozygous pups have severe polycystic kidney disease (16). In the current study, the homozygous animals 
had substantially enlarged kidneys, whether expressed as total kidney weight (data not shown) or as kidney 
weight as a percentage of overall BW (Figure 5B). Importantly, the kidney weight was not altered by TRPV4 
antagonist treatment. Overall brain weights were not different across genotypes; however, when expressed as a 
percentage of BW, the brain weights in the homozygous animals were significantly higher (Figure 5C).
Total amount of  TRPV4 in CP is not changed by disease or drug treatment. The rat is not the canonical model 
for studying electrolyte transport in the CP; therefore, we conducted PCR studies using freshly isolated 
CPs to confirm the presence of  TRPV4 and other well-known transport proteins that have been demon-
strated to be important in CP-mediated production of  CSF (8). Figure 6 shows the reverse transcription 
PCR (RT-PCR) results indicating the presence of  the apical membrane transporters, aquaporin 1 (AQP1), 
Na+K+ ATPase subunits α1 and β2, volume regulated ion channel, Na+K+2Cl– cotransporter, TMEM16A 
chloride channel, and TRPV4, as well as the basolateral membrane transporters, anion exchanger 2, sodi-
um bicarbonate cotransporter, and the electrogenic sodium bicarbonate exchanger. In a previous study, we 
Figure 3. Representative MRI Scans Before and After Treatment with RN 1734. MRI Images of P7 and P14 WT 
(Tmem67+/+), heterozygous (Tmem67+/–), and homozygous/hydrocephalic (Tmem67–/–) rats demonstrating the size of 
the lateral ventricles before and after treatment with vehicle or RN 1734. The images are shown as coronal, sagittal, 
and horizontal plane images, and a 3D rendering of the lateral ventricles. Red and green are pseudocolors of the right 
and left lateral ventricles to provide additional definition of the fluid compartments.
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documented the importance of  Ca2+-activated potassium channels in TRPV4-mediated transepithelial ion 
flux (10). The rat CP expressed the intermediate conductance K+ channel (IK), as well as all 3 isoforms of  
the small conductance channels (SK1, SK2, and SK3).
Quantitative PCR (qPCR) of isolated CPs was used to determine potential changes in the gene expression 
of key signaling components, which might be expected to change as a function of disease development and/or 
treatment (Figure 6D). There was a statistically significant increase in AQP1 as a result of hydrocephalus (1.86 ± 
0.29 relative to WT), and this was not reversed by antagonist treatment (1.95 ± 0.44). NKCC1, a triple cotrans-
porter that has been implicated in CSF production, was increased by antagonist treatment in the WT animals 
(1.66 ± 0.04). The hydrocephalic state also caused an increase in expression of the NKCC1 (1.82 + 0.15), but this 
did not reach significance in the hydrocephalic, antagonist-treated animals. Compared with WT, TRPV4 gene 
expression did not change in response to antagonist treatment in the WT animals, nor was it statistically altered 
in the untreated hydrocephalic animals. Interestingly, there was a small but statistically significant decrease in 
TRPV4 mRNA in the treated, hydrocephalic animals. IK showed a trend toward lower levels in the homozy-
gous animals, and this reached significance only in the antagonist treated homozygous group. Na+K+ ATPase 
α1 subunit increased moderately in the WT, treated animals but was unaffected in the hydrocephalic state. The 
TMEM16a chloride channel and the Na+K+ ATPase β2 subunit were unchanged by phenotype or treatment.
Figure 4. Quantitative measurements of amelioration of ventriculomegaly in hydrocephalic Tmem67–/– rats by 
treatment with a TRPV4 antagonist, RN 1734. (A–C) WT (Tmem67+/+), heterozygous (Tmem67+/–), and homozygous/
hydrocephalic (Tmem67–/–) ventricular volumes (mm3) at P7 and P15 in animals treated with either vehicle or RN 1734. 
(D) Change in ventricular volume (delta, Δ) from P7 to P15 for each genotype and treatment group. WT, vehicle (n = 11); 
WT, RN 1734 (n = 12); Het, vehicle (n = 14); Het, RN 1734 (n = 11); Hom, vehicle (n = 11); Hom, RN 1734 (n = 12). All data 
shown are the mean ± SEM for each group. Significance values were determined by 2-way ANOVA test in Prism using 
genotype and treatment as variables. Het, heterozygous; Hom, homozygous/hydrocephalic; vehicle = DMSO/saline 
daily i.p. injection; RN 1734, RN 1734, TRPV4 antagonist; 4 mg/kg BW i.p. daily injection.
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Given the importance of  TRPV4 as a hub protein, the qPCR results were confirmed by Western blot-
ting of  tissue from freshly isolated CPs (Figure 7). Western blots of  total protein isolated from CP tissue 
indicate that there is no significant change in TRPV4 protein expression between untreated WT and homo-
zygous animals as normalized to either β-actin or Ponceau S loading controls (Figure 7, A and B). The 
observed number of  distinct bands recognized by the anti-TRPV4 antibody is unusual. Therefore, addi-
tional blotting and specificity studies were performed. Antibody specificity was determined by immunopre-
cipitation and subsequent detection by MS/MS at the Indiana University Proteomics Core. The MS/MS 
analysis confirmed that TRPV4 was immunoprecipitated by the antibody (data not shown). Additionally, 
immunoprecipitation with an IgG control was also used as a specificity determinant (data not shown).
The presence of  4 distinct TRPV4 bands in the CP as opposed to 2 bands in kidney tissue from the 
same animals (Figure 7C) indicated the presence of  multiple isoforms and/or posttranslational modifica-
tion of  the protein. To determine if  the protein was glycosylated, samples were treated with PNGaseF to 
deglycosylate an aliquot of  the samples before running on a gel in tandem with the untreated samples. The 
deglycosylation resulted in a single protein band in the samples obtained from the kidney and 2 distinct 
bands in the proteins of  the CP (Figure 7C). To our knowledge, this is the first demonstration of  glycosylat-
ed isoforms of  TRPV4 in the CP that are distinct from the isoform found in renal tissue. The glycosylation 
patterns are interesting and indicate that similar levels of  expression of  glycosylated and nonglycosylated 
forms of  the transporter exist in the CP.
The finding that the amount of  TRPV4 did not change suggests that the mechanism of  the TRPV4 
effect on CSF production could be mediated via a change in cell surface expression or an activation of  
channels already present on the cell membrane.
Mechanism of  action of  TRPV4 in CP. TRPV4 is a nonspecific cation channel whose activation is usually 
associated with the influx of  Ca2+ (14, 21). However, the nonselective nature of  the channel allows for the 
transport of  other cations, notably Na+ (22). The changes in intracellular ion concentrations secondarily alter 
other channels and transporters leading to the transepithelial flux of  both electrolytes and water (10, 11, 23).
Figure 8A shows the effect of  TRPV4 activation on the influx of  Ca2+ in freshly isolated CP from the 
rat model. Activation of  TRPV4 with an agonist caused an immediate increase in intracellular Ca2+ that 
was similar to the positive control using the Ca2+ ionophore, ionomycin, to induce Ca2+ influx. Interestingly, 
using a sodium indicator showed that channel activation simultaneously stimulated the influx of  extracel-
lular Na+ in CP, which is similar to that observed with the Na+ ionophore nystatin (Figure 8B). These sub-
stantial and immediate changes in the intracellular ionic concentrations will undoubtedly cause compensa-
tory activation of  other channels and intracellular signaling pathways, leading to transepithelial electrolyte 
and fluid flux such as that observed by multiple investigators, including ourselves (10, 11, 23, 24).
Figure 5. Effect on BW and organ size by treatment with TRPV4 antagonist RN 1734. (A–C) BWs (A), kidney weights (B) (combined left and right) 
expressed as a function of BW, and wet, intact brain weights (C) expressed as a function of BW collected at P15 for all groups. WT, vehicle (n = 11); WT, RN 
1734 (n = 12); Het, vehicle (n = 14); Het, RN 1734 (n = 11); Hom, vehicle (n = 11); Hom, RN 1734 (n = 12). All data shown are the mean ± SEM for each group. 
Significance values were determined by 2-way ANOVA test in Prism using genotype and treatment as variables. Het, heterozygous; Hom, homozygous/
hydrocephalic; vehicle = DMSO/saline daily i.p. injection; RN 1734, RN 1734, TRPV4 antagonist; 4 mg/kg BW i.p. daily injection
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Figure 6. mRNA expression of water and electrolyte transporters and channels in native rat choroid plexus. (A–C) RT-PCR gels showing the presence of 
selected apical transporters (A), basolateral transporters (B), and potassium channels (C) in native rat choroid plexus tissue. (D) qPCR of WT and hydrocephal-
ic (Hom) untreated (Untr) and RN 1734–treated (RN) choroid plexus (n = 3, each in triplicate) with TRPV4, AQP1 (WT RN, n = 2), NKCC1, TMEM16A, IK, Na+/
K+ ATPase α (NKa) subunit and Na+/K+ ATPase β (NKb) subunit primers. RN treated choroid plexus tissue from homozygous animals showed a significant 
decrease (***P < 0.0001) in TRPV4 mRNA expression relative to untreated WT tissue. RN and Untr tissue from homozygous animals demonstrated signifi-
cant (*P < 0.05) increases in AQP1 mRNA expression relative to untreated WT tissue. RN treated WT and Untr homozygous tissue also exhibited significant 
(*P < 0.05) increases in NKCC1 mRNA expression relative to untreated WT tissue. RN treated homozygous tissue had a significant (**P < 0.01) decrease in IK 
mRNA relative to untreated WT tissue. NKa mRNA increased significantly (**P < 0.01) in RN treated WT animals relative to untreated WT tissue. TMEM16A 
and NKb did not have any significant changes in mRNA regardless of genotype or treatment. Significance values were determined by unpaired t test calculat-
ed in Prism. AQP1, aquaporin 1; ATP1A1/B2, ATPase Na+/K+ Transporting Subunits α1/β2; LRRC8A, volume regulated anion channel; NKCC1, sodium, potassi-
um, chloride cotransporter 1; TMEM16A, anoctamin-1 chloride channel; TRPV4, transient receptor potential vanilloid 4; AE2, acid exchanger 2; NBCe2, sodium 
bicarbonate cotransporter; NCBE, electrogenic sodium bicarbonate exchanger 1; BK, large conductance potassium channel; IK, intermediate conductance 
potassium channel; SK1/2/3, small conductance potassium channels 1/2/3. Primer information for can be found in Supplemental Table 1.
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Discussion
Although investigators have been attempting to develop nonsurgical treatments for hydrocephalus for 
over 60 years, successes in preclinical animal studies have not translated well into clinical trials (25). 
In part, this may be due to preclinical models that do not accurately recapitulate the human condi-
tion initiation or progression. For example, one of  the most common models of  induced pediatric 
hydrocephalus involves injections of  kaolin into the cisterna magna or the cerebral ventricles. This 
generally produces an obstructive form of  hydrocephalus, but it has been well recognized that kaolin 
is a caustic chemical that causes denudation of  the epithelial cells lining the CP and ventricular wall 
(26). Therefore, this treatment destroys the barrier epithelial cells that one wishes to study with regard 
to the control of  CSF production and whose dysregulation may contribute to the pathological changes 
that lead to hydrocephalus. The development of  models that reflect the pathological and compensatory 
changes that occur during hydrocephalic development are necessary before preclinical studies will be 
translatable to patients. Our current studies were performed in a genetic rat model, which is more phys-
iologically relevant to the clinical condition.
Commonalities in the communicating forms of  hydrocephalus include ventricular enlargement cou-
pled with an imbalance in fluid-electrolyte homeostasis. This can be due to overproduction or underab-
sorption of  CSF. Alternatively, there may be a change in the ionic composition of  the CSF, leading to fluid 
accumulation via osmotic forces. Regardless of  the initiating cause of  the disease, treating the changes in 
Figure 7. Expression of TRPV4 channel in native rat choroid plexus. (A) Immunoblotting of WT choroid plexus (WT CPe) and hydrocephalic choroid plexus 
(Hom CPe) for TRPV4 protein using β-actin and Ponceau S loading controls, showing no substantial change in protein expression of TRPV4 due to genotype. (B) 
Immunoblotting of WT kidney (WT Kid), hydrocephalic kidney (Hom Kid), WT choroid plexus (WT CPe), and hydrocephalic choroid plexus (Hom CPe) for TRPV4. 
(C) Deglycosylation of TRPV4 with PNGaseF enzyme with matched untreated inputs demonstrating that there are 2 isoforms of TRPV4, both of which are 
glycosylated in the choroid plexus. There is only 1 isoform of TRPV4 in the kidney, but it is also glycosylated. Significance values were determined by paired t test 
in Prism between experimental groups, and no significant differences were found.
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fluid-electrolyte balance may provide an effective treatment. Therefore, good targets for drug development 
are the electrolyte transport proteins of  the epithelial cells of  the CP that are responsible for the production 
and unique composition of  the CSF, particularly those that are likely to be activated by pathophysiological 
changes such as inflammatory mediators or alterations in pressure or fluid flux.
In the Tmem67–/– genetic model of  communicating hydrocephalus, we have shown that 2 different 
TRPV4 antagonists inhibit the development of  ventriculomegaly. These data are in agreement with in 
vitro studies in cultured CP epithelia demonstrating that TRPV4 agonists stimulate a multiphasic tran-
sepithelial ion flux that can be inhibited by either of  the 2 antagonists used in the current study (10–12). 
The mechanism of  action and the role of  TRPV4 in the development of  hydrocephalus do not appear to 
be dependent on increased expression of  the channel protein, suggesting that the mechanism is, rather, 
a change in cell surface expression and/or activation. This finding is also in agreement with the cell 
culture data where activation of  TRPV4 changes epithelial permeability and transepithelial ion trans-
port within minutes (10, 11), not within the hours required for new protein synthesis. These data are 
consistent with the hypothesis that TRPV4 is activated by the pathophysiological changes that initiate 
the process of  hydrocephalus. TRPV4 has been shown to be activated by multiple inputs from chemical 
(arachidonic acid metabolites and cytokines) to physical changes (pressure and osmotic changes) (14, 
21). All of  these are applicable within the myriad causes of  hydrocephalus. In this regard, it should be 
noted that the TRPV4 antagonists do not appear to alter ventricular volumes in normal animals and 
are, therefore, applicable primarily in the hydrocephalic state. We speculate that our findings of  TRPV4 
antagonist–mediated inhibition of  the development of  hydrocephalus will be applicable to most forms 
of  the disease and could be used on an as-needed basis.
Other key transport elements show only moderate changes in expression due to hydrocephalus. Treat-
ment with the TRPV4 antagonist does not restore the AQP1 to control levels, indicating an independence 
in cell signaling between AQP1 and TRPV4. Interestingly, blocking TRPV4 causes an increase in NKCC1 
in the WT animals, potentially as a compensatory change in electrolyte flux across the tissue. This increase 
in the triple cotransporter is also seen in response to the hydrocephalic state, but the increase, while trend-
ing higher, was not statistically maintained during antagonist treatment. These results are preliminary but 
indicate a complex regulation of  water/electrolyte balance that deserves further study.
Pharmacologically altering the production of  CSF is a promising approach with the potential to rev-
olutionize treatment and spare patients the cost and morbidity related to surgery. TRPV4 inhibitors are in 
clinical trials for a variety of  other indications. GlaxoSmithKline (GSK) has completed several short-term 
clinical trials using GSK2798745, an orally bioavailable TRPV4 channel blocker (https://clinicaltrials.gov.). 
Figure 8. TRPV4 activation elicits functional sodium and calcium influx into ex vivo rat choroid plexus. (A) Ex vivo choroid plexus was incubated in 
Fluo-4 calcium indicator dye to study calcium influx into the epithelial cells. Ionomycin (100 μM) was used as a positive control for calcium influx, and 
GSK1016790A (3 nM) was used to agonize TRPV4. TRPV4 activation generated a qualitative increase in fluorescent signal, consistent with allowing cal-
cium influx into the cells. (B) Ex vivo choroid plexus was incubated in CoroNa Green Sodium indicator dye to study sodium influx into the epithelial cells. 
Nystatin (100 μM) was used as a positive control for sodium influx, and GSK1016790A (3 nM) was used to agonize TRPV4. TRPV4 activation generated 
a qualitative increase in fluorescent signal, consistent with allowing sodium influx into the cells. TRPV4, transient receptor potential vanilloid 4; GSK, 
GSK1016790A. Original magnification, 40×.
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In a 7-day trial in patients with congestive heart failure, the primary measure of  changes in pulmonary gas 
transfer and respiration was not statistically analyzed because of  small sample size (n = 11). Importantly, 
there was neither mortality nor any serious adverse clinical effects attributable to the drug. Subsequently, 
GSK conducted additional human studies for chronic cough and alveolar barrier disruption in segmental 
LPS challenge. In both of  these studies, the investigators declined to analyze outcomes but also reported no 
mortality and no serious adverse effects in any of  the volunteers. Finally, a recent report describes the first-in-
human study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of  GSK2798745 in 
healthy subjects and stable heart failure patients. Five cohorts contained a total of  60 participants who were 
treated with the TRPV4 antagonist (27). Again, the drug was well tolerated, and there was no mortality and 
were no serious adverse clinical effects. These human studies suggest that inhibiting TRPV4 will have min-
imal side effects, at least in the short-term. This was presaged by animal studies that showed that Trpv4-null 
mice have a normal appearance, growth, and reproductive capacity and only develop osmotic abnormalities 
when placed under severe osmotic stress (28). The published studies combined with our current data suggest 
that inhibition of  TRPV4 may be a safe and effective treatment for some forms of  hydrocephalus.
Methods
Study design. The objective of  this research was to test the effect of  TRPV4 antagonists on ventricular vol-
ume in a genetic rat model of  hydrocephalus, Tmem67–/–. The rat colony was provided by Vincent Gattone 
(Department of  Anatomy and Cell Biology, Indiana University School of  Medicine, Indianapolis, Indiana, 
USA). Based on preliminary head dimension data, it was hypothesized that the TRPV4 antagonists would 
reduce ventricular volume in the hydrocephalic rat pups. These were controlled laboratory experiments, 
and details of  the treatment and measurement methods can be found in the Results sections. Animals in 
these studies were randomly chosen for either vehicle or drug treatment. Head dimension measurement 
series were conducted by the same observer who was blinded to the genotype of  the animals. In subsequent 
studies, the MRI imaging technicians and analysts were blinded to both genotype and treatment of  the ani-
mals. Animals were excluded from the study only by death before the final MRI (5 animals). Heterozygous 
Tmem67+/– animals were bred to generate WT (Tmem67+/+), heterozygous (Tmem67+/–), and homozygous 
(Tmem67–/–) pups to be used in treatment studies.
Genotyping. Tail snip samples were collected from pups before P3. DNA was extracted using the 
reagents and protocol of  the QIAGEN QIAamp DNA Mini Kit 250 (catalog 51306). After extraction, 
PCR was performed using 0.25 μL mixture of  primers 5′ AGA AAA GTT CTT CAC TGG TTG ACA 
3′ (forward) and 5′ CAT CAT CAT CCC TGG TTC CTG 3′ (reverse), 6.25 μL Quanta Bio’s AccuStart 
GelTrack PCR SuperMix (catalog 95136), and 4 μL DDI H2O. The reaction was run at 95°C for 2 
minutes, followed by 35 cycles of  95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 1 minute, 
followed by 72°C for 1 minute. After completion of  PCR, excess nucleotides were removed using 4 
μL of  applied biosystems ExoSAP-IT Express PCR Product Cleanup (catalog 750011). The reaction 
was run at 37°C for 1 minute, followed by 37°C for 14 minutes, and ending with 80°C for 15 minutes. 
Samples were sent to Eton Biosciences with the forward primer for sequencing to analyze the C1186T 
loci of  exon 12 of  the Tmem67 gene.
Head measurements. Before and after drug treatment (days listed in figure legends) both vertical (palate to 
cranial cap) and horizontal (biparietal) head measurements were taken using calipers. In the experimental 
series using the TRPV4 antagonists HC067047 and RN1743, the control group represented both WT and 
heterozygous animals. In this early experimental set, the complex genotyping had not yet been established, 
and the animals were characterized as homozygous or hydrocephalic, if  their kidneys were enlarged. Het-
erozygous animals do not have enlarged kidneys. We feel these head measurements are valid because the 
extent of  the hydrocephalus is not sufficient in the heterozygous animals to alter the head dimensions.
Treatment protocol for MRI study. Pups were randomly chosen for either vehicle or drug treatment. Pups 
underwent preliminary MRI on P7 and then were treated daily with an i.p. injection of  either RN 1734 (Toc-
ris, 3746), 4 mg/kg BW, or equal volume 100% DMSO vehicle. On P15, pups underwent final MRI; they 
were then sacrificed, and tissue was procured.
Anatomical MRIs. On P7 and P15, rat pups were briefly removed from their litter and induced with 
5% isoflurane (balance medical oxygen), and anesthesia was maintained with 1%–2% isoflurane (balance 
medical oxygen). High-resolution T2-weighted (T2W) MRI images were acquired using a 3T Siemens Pris-
ma clinical MRI scanner outfitted with a dedicated 4-channel rat head coil and bed system (RapidMR). 
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Images were acquired using a SPACE3D sequence with the following acquisition parameters: (TA:,5.5 
minutes; TR, 2080ms; TE, 162ms; ETL, 57; FS, On; Ave, 2; Excitation Flip Angle, 150; Norm Filter, 
On; Restore Magnetization, On; Slice Thickness, 0.2 mm: Matrix, 171 × 192; FOV, 35 × 35 mm) yielding 
0.18 × 0.18 × 0.2 mm resolution images. Volumes of  interest (VOI) of  lateral ventricles were determined 
from threshold-based image segmentation of  native cerebrospinal fluid contrast, where images were quan-
tified for lateral ventricular volumes using Analyze 12.0 (AnalyzeDirect). In all cases, study personnel were 
blinded to genotype and treatment during acquisition and analysis.
RT-PCR. Animals were euthanized via CO2 exposure followed by rapid decapitation, and brains were 
harvested. Lateral ventricle CPs were resected and flash frozen. Total cell RNA was collected using the Mon-
arch Total RNA Miniprep Kit (New England Biolabs, T2010S) using the manufacturer’s directions for mam-
malian tissue. RNA concentration was measured using an ND2000 NanoDrop (Thermo Fisher Scientific). 
Approximately 100 ng of  total RNA was reverse transcribed into cDNA using the Monarch LunaScript RT 
SuperMix Kit (New England Biolabs, E3010L), along with corresponding negative RT (–RT) cDNA control 
and a template control not containing RNA (NTC), according to the manufacturer’s directions. Rattus nor-
vegicus exon mRNA sequences for each gene were obtained using Ensembl, and primer pairs for each were 
designed using Primer3Plus. Approximately 500 ng of  template cDNA was combined with the forward and 
reverse primers (IDT), as well as GoTaq Green Master Mix (Promega Corporation, M7122). Reactions were 
run as a gradient to determine optimum annealing temperature for each primer pair, and products were sep-
arated on a 1.5% agarose gel with ethidium bromide. Flanking 100 bp ladders were used as molecular weight 
markers, and gels were imaged using a ChemiDoc XRS imager (Bio-Rad). Single band amplicons of  the 
correct molecular weight were sequenced (Eton Biosciences), and the correct products were validated using 
NCBI and Ensembl BLAST.
qPCR. CP RNA was collected and transcribed as described for RT-PCR. The cDNA was diluted with 
nuclease-free water (New England Biolabs). All samples were run in triplicate. qPCR was performed using 
a LightCycler 480 Instrument II real-time PCR system (Roche LifeScience), using LightCycler 480 SYBR 
Green I Master Mix (Roche LifeScience, 04707516001). qPCR cycle conditions were 95°C for 5 minutes, 
followed by 45 cycles of  95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 10 seconds. Data are 
displayed as relative fold change in expression using the 2–ΔΔCT method (29), relative to the calibrator house-
keeping genes GAPDH and Rps18. Data are shown as fold change in each compound of  interest in treated 
WT and treated and untreated homozygous animals relative to the normalized control (untreated WT) 
animals. Primers were validated by sequencing. Supplemental Table 1 contains primer information.
Western immunoblots. Animals were anesthetized and euthanized with rapid decapitation. The brain 
was harvested, and the lateral ventricle and third ventricle CPs were harvested and flash frozen. Samples 
were solubilized with low ionic lysis buffer (0.05% EDTA, 0.5% Triton X-100 [Thermo Fisher Scientific], 
0.1% Tris-HCl, 0.1% DTT, 0.1% protease inhibitor cocktail [BioMake], 0.5% sodium orthovanadate, 
0.5% sodium fluoride, 0.5% β-mercaptoethanol, 0.5% sodium pyrophosphate [all from MilliporeSigma]) 
with vigorous pipetting followed by brief  pulse sonication. Sample buffer (4×) was added, and samples 
were heated at 70°C. The resulting solubilized samples were run on a 10% gel at 200V for 45 minutes. 
Proteins were transferred to nitrocellulose membranes and were Ponceau S stained for total protein. Sub-
sequently, membranes were blocked with 5% nonfat milk (Carnation) in TBS-T and probed with rabbit 
anti-TRPV4 antibody (Invitrogen, PA5-77319) or a β-actin antibody (Proteintech, 60008-1-Ig) overnight 
at 4°C. The following day, the membranes were washed and blocked with 5% nonfat milk in TBS-T 
and then probed with secondary Alexa Fluor anti-mouse 690 nm or anti-rabbit 790 nm (Jackson Immu-
noResearch; 715-625-151 and 711-655-152, respectively) antibodies. Membranes were washed with TBS 
and visualized on a LICOR Odyssey machine. Deglycosylation was performed using PNGaseF enzyme 
recombinant (New England Biolabs, P0708S) according to the standard protocol provided by the com-
pany. Band intensities were quantified using the LICOR software and normalized to both β-actin and 
Ponceau S total protein stain as quantified using ImageJ software (NIH).
Cation dyes. Animals were briefly anesthetized and euthanized with rapid decapitation. The brain was 
removed, and lateral ventricle and third ventricle CPs were harvested and placed in warm DMEM high 
glucose without phenol red. Suspended tissues were allowed to equilibrate at 37°C for 30 minutes. Subse-
quently, tissues were incubated in either Fluo-4 AM dye (Invitrogen, F14201) or CoroNa Green AM dye 
(Invitrogen, C36676) for 30 minutes at 37°C according to Invitrogen protocols. Tissues were washed twice 
with DMEM high glucose without phenol red. The TRPV4 agonist, ionomycin, or nystatin were added, 
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and the tissues were imaged on a Keyence BZ-X800 epifluorescence scope. Image processing was done in 
the Keyence BZ-X800 Analyzer software, and figures were arranged in PowerPoint.
Statistics. Graphs were produced in Prism software; figures were arranged in Prism, PowerPoint, and 
Adobe Illustrator; and statistical analyses were performed using SigmaPlot (version 14, Systat Software 
Inc.). Power analysis was performed routinely until the power of  the study exceeded 0.50 (50%). Data were 
tested for normality using the Shapiro-Wilk test, and equal variance was tested using the Brown-Forsythe 
test. Normally distributed data were analyzed using 2-tailed Student’s t test or 2-way ANOVA when com-
paring 2 or 3 groups, respectively. Nonnormally distributed data were analyzed using the nonparametric 
Mann-Whitney U and the Holm-Šidák method post hoc tests, which compare 2 and 3 data groups, respec-
tively. Data were expressed as mean ± SEM, and P < 0.05 was considered significant.
Study approval. Animal experiments were performed under approved protocols from the IACUC of  
Indiana University, Purdue University, Indianapolis.
Author contributions
AEH and HMS contributed equally to the project and, thus, serve as co–first authors. They are listed in 
alphabetical order. AEH, HMS, and BLBY drafted the manuscript and prepared figures. AEH helped with 
animal studies and the development of  genotyping, performed immunoblotting and ex vivo CP imaging, 
and generated figures for the manuscript. HMS designed and conducted animal studies and genotyping, 
and generated figures for the manuscript. PRT designed and directed the MRI studies. DCP and MMR 
designed and conducted PCR and qPCR studies. JWS was involved in the early animal studies and contrib-
uted to development of  genotyping. DF served as a clinical consultation in these studies. BLBY designed 
experiments, conducted data analyses, verified all data in the manuscript for accuracy, and finalized the 
manuscript. All authors have read and approved the submitted version of  the manuscript.
Acknowledgments
The authors would like to thank A.J. Baucum II and Darryl Watkins for advice and training on the LICOR 
equipment for quantification of  Western blots and general trouble shooting with glycosylation reactions. 
We would also like to acknowledge Nicolas Berbari for help with the qPCR methods and advice on animal 
husbandry; Amanda Bedwell for logistical support during the transport and sedation of  rats, which was 
necessary to conduct the MRIs; and Scott Persohn for quantification of  MRI volumes. This work was 
supported by the following grants: The Indiana Clinical and Translational Sciences Institute by grant no. 
UL1TR001108 from the NIH; National Center for Advancing Translational Sciences, Clinical and Trans-
lational Award (BBY and DF); a Hydrocephalus Association/Team Hydro Innovator Award (BBY); and 
the Office of  the Assistant Secretary of  Defense for Health Affairs, through the Peer Reviewed Medical 
Research Program, Investigator Initiated Research Award under Award No. W81XWH-17-1-0537 (BBY). 
Address correspondence to: Bonnie L. Blazer-Yost, 723 W Michigan Street, SL 306, Indianapolis, Indiana 
46202, USA. Phone: 317.278.1145; Email: bblazer@iupui.edu.
JWS’s present address is: College of  Information Technology and Engineering, Marshall University, Hun-
tington, West Virginia, USA.
 1. Simon TD, et al. Hospital care for children with hydrocephalus in the United States: utilization, charges, comorbidities, and 
deaths. J Neurosurg Pediatr. 2008;1(2):131–137.
 2. Dewan MC, et al. Global hydrocephalus epidemiology and incidence: systematic review and meta-analysis. J Neurosurg. 
2019;130(4):1065–1079.
 3. Williams MA, Malm J. Diagnosis and Treatment of  Idiopathic Normal Pressure Hydrocephalus. Continuum (Minneap Minn). 
2016;22(2 Dementia):579–599.
 4. Guyot LL, Michael DB. Post-traumatic hydrocephalus. Neurol Res. 2000;22(1):25–28.
 5. Kammersgaard LP, Linnemann M, Tibæk M. Hydrocephalus following severe traumatic brain injury in adults. Incidence, tim-
ing, and clinical predictors during rehabilitation. NeuroRehabilitation. 2013;33(3):473–480.
 6. Mazzini L, Campini R, Angelino E, Rognone F, Pastore I, Oliveri G. Posttraumatic hydrocephalus: a clinical, neuroradiologic, 
and neuropsychologic assessment of  long-term outcome. Arch Phys Med Rehabil. 2003;84(11):1637–1641.
 7. Drake JM, et al. Randomized trial of  cerebrospinal fluid shunt valve design in pediatric hydrocephalus. Neurosurgery. 
1998;43(2):294–303.
 8. Damkier HH, Brown PD, Praetorius J. Cerebrospinal fluid secretion by the choroid plexus. Physiol Rev. 2013;93(4):1847–1892.
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.137646
R E S E A R C H  A R T I C L E
 9. Liedtke W, et al. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell. 
2000;103(3):525–535.
 10. Preston D, et al. Activation of  TRPV4 stimulates transepithelial ion flux in a porcine choroid plexus cell line. Am J Physiol, Cell 
Physiol. 2018;315(3):C357–C366.
 11. Simpson S, Preston D, Schwerk C, Schroten H, Blazer-Yost B. Cytokine and inflammatory mediator effects on TRPV4 function 
in choroid plexus epithelial cells. Am J Physiol, Cell Physiol. 2019;317(5):C881–C893.
 12. Vincent F, et al. Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009;389(3):490–494.
 13. Wu L, Gao X, Brown RC, Heller S, O’Neil RG. Dual role of  the TRPV4 channel as a sensor of  flow and osmolality in renal 
epithelial cells. Am J Physiol Renal Physiol. 2007;293(5):F1699–1713.
 14. White JPM, Cibelli M, Urban L, Nilius B, McGeown JG, Nagy I. TRPV4: Molecular Conductor of  a Diverse Orchestra. Physi-
ol Rev. 2016;96(3):911–973.
 15. Darby WG, Grace MS, Baratchi S, McIntyre P. Modulation of  TRPV4 by diverse mechanisms. Int J Biochem Cell Biol. 
2016;78:217–228.
 16. Gattone VH, et al. Development of  multiorgan pathology in the wpk rat model of  polycystic kidney disease. Anat Rec A Discov 
Mol Cell Evol Biol. 2004;277A(2):384–395.
 17. Smith UM, et al. The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat 
Genet. 2006;38(2):191–196.
 18. Shim JW, et al. Hydrocephalus in a rat model of  Meckel Gruber syndrome with a TMEM67 mutation. Sci Rep. 2019;9(1):1069.
 19. Kulkarni AV, Cochrane DD, McNeely PD, Shams I. Medical, social, and economic factors associated with health-related quali-
ty of  life in Canadian children with hydrocephalus. J Pediatr. 2008;153(5):689–695.
 20. Kartal MG, Algin O. Evaluation of  hydrocephalus and other cerebrospinal fluid disorders with MRI: An update. Insights Imag-
ing. 2014;5(4):531–541.
 21. Kanju P, Liedtke W. Pleiotropic function of TRPV4 ion channels in the central nervous system. Exp Physiol. 2016;101(12):1472–1476.
 22. Voets T, et al. Molecular determinants of permeation through the cation channel TRPV4. J Biol Chem. 2002;277(37):33704–33710.
 23. Takayama Y, Shibasaki K, Suzuki Y, Yamanaka A, Tominaga M. Modulation of  water efflux through functional interaction 
between TRPV4 and TMEM16A/anoctamin 1. FASEB J. 2014;28(5):2238–2248.
 24. Narita K, et al. TRPV4 regulates the integrity of  the blood-cerebrospinal fluid barrier and modulates transepithelial protein 
transport. FASEB J. 2015;29(6):2247–2259.
 25. Del Bigio MR, Di Curzio DL. Nonsurgical therapy for hydrocephalus: a comprehensive and critical review. Fluids Barriers 
CNS. 2016;13:3.
 26. Hochwald GM, Sahar A, Sadik AR, Ransohoff  J. Cerebrospinal fluid production and histological observations in animals with 
experimental obstructive hydrocephalus. Exp Neurol. 1969;25(2):190–199.
 27. Goyal N, et al. Clinical Pharmacokinetics, Safety, and Tolerability of  a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, 
GSK2798745, in Healthy and Heart Failure Subjects. Am J Cardiovasc Drugs. 2019;19(3):335–342.
 28. Liedtke W, Friedman JM. Abnormal osmotic regulation in trpv4-/- mice. Proc Natl Acad Sci U S A. 2003;100(23):13698–13703.
 29. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108.
